Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-90009 |
Synonyms | |
Therapy Description |
CC-90009 binds to the ubiquitin E3 ligase complex member cereblon (CRBN), which may lead to increased ubiquitination and proteosomal degradation of substrate proteins, including proteins involved in immune system activity or cell proliferation (PMID: 29788898). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-90009 | CC 90009 | CC-90009 binds to the ubiquitin E3 ligase complex member cereblon (CRBN), which may lead to increased ubiquitination and proteosomal degradation of substrate proteins, including proteins involved in immune system activity or cell proliferation (PMID: 29788898). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02848001 | Phase I | CC-90009 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | Terminated | USA | NOR | GBR | FRA | ESP | CAN | 0 |